The problem of transplanting the sensitized patient: Whose problem is it?

被引:27
作者
Jackson, Annette M. [1 ]
Zachary, Andrea A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Immunogenet Lab, Baltimore, MD 21205 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2008年 / 13卷
关键词
transplantation; HLA; PRA; sensitization; alloantibodies; rejection; review;
D O I
10.2741/2770
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transplantation is the treatment of choice for end-stage renal failure and a life-saving treatment for failure of other major organs. Improvements in surgical techniques, histocompatibility testing, and immunosuppressive drugs have significantly improved both patient and graft survival (1-4). However, there are formidable barriers to the successful transplantation of patients who possess HLA-specific antibodies. Sensitized patients wait longer for a transplant and, once transplanted, experience more rejection episodes and have decreased graft survival compared to non-sensitized recipients (5-8). Improvements in HLA-specific antibody detection have expanded the donor pool available to sensitized patients (914) and desensitization protocols designed to reduce the breadth and amount of HLA-specific antibody have found increased success during the last decade (15-20). Determining the appropriate course of treatment for the sensitized patient requires accurate immunologic characterization and clinical assessment of the patient. Together, the transplant physician and histocompatibility expert must determine what constitutes a compatible donor and assess the patient's risk for a particular transplant. Thus, sensitization to HLA antigens is a problem for the patient, the transplant physician, and the histocompatibility laboratory.
引用
收藏
页码:1396 / 1412
页数:17
相关论文
共 174 条
[61]   Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action [J].
Jordan, SC ;
Quartel, AW ;
Czer, LSC ;
Admon, D ;
Chen, G ;
Fishbein, MC ;
Schwieger, J ;
Steiner, RW ;
Davis, C ;
Tyan, DB .
TRANSPLANTATION, 1998, 66 (06) :800-805
[62]   Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation [J].
Jurcevic, S ;
Ainsworth, ME ;
Pomerance, A ;
Smith, JD ;
Robinson, DR ;
Dunn, MJ ;
Yacoub, MH ;
Rose, ML .
TRANSPLANTATION, 2001, 71 (07) :886-892
[63]   Overcoming barriers to long-term graft survival [J].
Kaplan, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) :S52-S64
[64]   Successful rescue of refractory, severe antibody mediated rejection with splenectomy [J].
Kaplan, Bruce ;
Gangemi, Antonio ;
Thielke, James ;
Oberholzer, Jose ;
Sankary, Howard ;
Benedetti, Enrico .
TRANSPLANTATION, 2007, 83 (01) :99-100
[65]   A computer match program for paired and unconventional kidney exchanges [J].
Kaplan, I ;
Houp, JA ;
Leffell, MS ;
Hart, JM ;
Zachary, AA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (09) :2306-2308
[66]   THE OCCURRENCE OF CYTOTOXIC AND NONCOMPLEMENT-FIXING ANTIBODIES IN THE CROSS-MATCH SERUM OF PATIENTS WITH EARLY ACUTE REJECTION EPISODES [J].
KARUPPAN, SS ;
OHLMAN, S ;
MOLLER, E .
TRANSPLANTATION, 1992, 54 (05) :839-843
[67]  
KATZNELSON S, 1997, CLIN TRANSPLANTS
[68]   Advances in immunology: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. [J].
Kazatchkine, MD ;
Kaveri, SV .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (10) :747-755
[69]   Current issues in pediatric transplantation [J].
Kelly, D. A. .
PEDIATRIC TRANSPLANTATION, 2006, 10 (06) :712-720
[70]   POSSIBLE CONTRIBUTION OF PRETRANSPLANT IMMUNE RESPONDER STATUS TO RENAL-ALLOGRAFT SURVIVAL DIFFERENCES OF BLACK VERSUS WHITE RECIPIENTS [J].
KERMAN, RH ;
KIMBALL, PM ;
VANBUREN, CT ;
LEWIS, RM ;
KAHAN, BD .
TRANSPLANTATION, 1991, 51 (02) :338-342